Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2003

View Archived Issues

Gabapentin combined with valaciclovir reduces severity and duration of postherpetic neuralgia

MBI-594AN solution safe and effective for reducing acne lesions

Long-lasting antitumor activity reported for Bexxar in refractory B-cell lymphoma

Combination therapy containing zosuquidar reverses multidrug resistance in AML

New data on subantimicrobial doses of Periostat discussed in San Antonio

New PARP inhibitors prepared and tested at Guilford

Pharma Mar identifies new antitumor ecteinascidin derivatives

Novel series of sPLA2 inhibitors described in Lilly patent

Takeda claims new CCR5 antagonists for HIV infection and other uses

Actelion scientists present novel series of endothelin antagonists

Benzopyran beta3-adrenoceptor agonists in Glenmark development pipeline

NeuroSearch describes novel inhibitors of CNS monoamine uptake

Potent alpha-adrenoceptor antagonists with utility in sexual dysfunction

Novel GnRH antagonists discovered by Neurocrine scientists

Lilly advances LY-818 into phase II

GL-48656 preclinical data reported

Galen's Femring approved by U.S. FDA

Incyte Genomics completes acquisition of Maxia

Vernalis reviews 2002 developments

Chronic antagonism of the CB1 receptor results in antiobesity effects in mice

Albaconazole, a broad-spectrum antifungal agent with a favorable overall profile

Methods of prophylaxis and treatment of HER-2/neu tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...